Back to Authors

Swords, Ronan T

0000-0003-3319-1870

Mayo Clinic

Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL.

Citations 1

Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML

Blood | January 18, 2018 | Volume: 131 | Issue: 13 | Pages: 1415-1424

10.1182/blood-2017-09-805895 | PMID 29348128

Key Points RP2D of PEV 20 mg/m2 in PEV/AZA combo did not alter toxicity profile of AZA; dose-limiting toxicities were transiently elevated AST/ALT. In treatment-naive older AML patients, the intent-to-treat ORR was 50%.